ORTHO-CEPT
LOE ApproachingNDAORAL-28TABLET
Approved
Dec 1992
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 18h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ORTHO-CEPT is an oral contraceptive tablet approved in 1992 by Johnson & Johnson. The specific indications and mechanism are not publicly detailed in available data, but it is a hormonal small-molecule formulation delivered as a 28-day cycle tablet. It represents a mature, established product in the contraceptive market.
LOE Approaching
LOE-stage product with moderate competitive pressure (30%) suggests declining market share and contracted brand team focus on transition planning and market defense.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job postings indicate a mature, stable-state product with minimal active hiring or team expansion. Roles available are primarily focused on defending market position and managing the transition to generic competition.
Brand ManagerProduct Manager
Worked on ORTHO-CEPT at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.